Jenburkt Pharmaceuticals Limited (BOM:524731)

Jenburkt Pharmaceuticals Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	96.48	73.65	41.25	36.6	50.31	24.94
Short-Term Investments	-	157.79	698.44	458.25	415.55	495.14
Cash & Short-Term Investments	96.48	231.43	739.69	494.84	465.86	520.07
Cash Growth	-87.58%	-68.71%	49.48%	6.22%	-10.42%	-4.67%
Accounts Receivable	227.55	207.35	194.75	169.62	152.07	140.01
Other Receivables	1.58	11	50.02	42.28	21.31	43.02
Receivables	233.04	218.87	245.67	213.08	175.28	184.14
Inventory	101.75	88.8	85.66	83.38	98.98	76.17
Prepaid Expenses	-	11.59	6.77	4.59	5.53	4.36
Other Current Assets	22.44	14.61	19.49	15.02	13.39	15.13
Total Current Assets	453.71	565.32	1,097	810.91	759.04	799.87
Property, Plant & Equipment	655.37	547.06	112.14	112.19	113.05	104.47
Long-Term Investments	958.76	767.44	173.9	344.09	415.71	209.79
Goodwill	-	-	-	-	-	0.01
Other Intangible Assets	3.77	2.28	3.88	1.87	3.06	4.8
Long-Term Deferred Tax Assets	8.02	14.69	7.98	4.25	3.71	7.37
Other Long-Term Assets	10.92	64.89	255.51	144.23	133.59	84.71
Total Assets	2,091	1,962	1,651	1,418	1,429	1,212
Accounts Payable	95.42	81.55	62.57	60.97	71.1	45.92
Accrued Expenses	10.34	16.04	9.31	2.55	2.59	12.73
Short-Term Debt	-	19.79	-	24.39	58.15	37.11
Current Portion of Leases	4.4	4.23	-	4.89	4.51	4.17
Current Income Taxes Payable	16.49	2.86	16.41	3.37	0.77	2
Other Current Liabilities	82.57	63.72	75.49	61.46	75.67	78
Total Current Liabilities	209.22	188.19	163.79	157.62	212.8	179.92
Long-Term Leases	12.67	14.92	-	-	4.89	9.4
Long-Term Deferred Tax Liabilities	9.87	10.87	7.9	7.18	8.56	8.21
Other Long-Term Liabilities	30.11	30.1	29.91	29.43	29.43	29.65
Total Liabilities	261.87	244.09	201.59	194.22	255.67	227.17
Common Stock	44.13	44.13	44.13	44.13	45.89	45.89
Retained Earnings	-	1,657	1,375	1,165	1,119	942.57
Comprehensive Income & Other	1,785	16.76	30.62	15.25	9.2	-3.8
Shareholders' Equity	1,829	1,718	1,449	1,224	1,174	984.66
Total Liabilities & Equity	2,091	1,962	1,651	1,418	1,429	1,212
Total Debt	17.08	38.94	-	29.28	67.55	50.67
Net Cash (Debt)	79.41	192.5	739.69	465.57	398.31	469.4
Net Cash Growth	-89.49%	-73.98%	58.88%	16.89%	-15.15%	-4.92%
Net Cash Per Share	17.99	43.62	167.61	101.97	86.79	102.28
Filing Date Shares Outstanding	4.41	4.41	4.41	4.41	4.59	4.59
Total Common Shares Outstanding	4.41	4.41	4.41	4.41	4.59	4.59
Working Capital	244.49	377.12	933.49	653.29	546.24	619.95
Book Value Per Share	414.40	389.23	328.42	277.32	255.77	214.55
Tangible Book Value	1,825	1,715	1,446	1,222	1,171	979.85
Tangible Book Value Per Share	413.55	388.71	327.54	276.90	255.10	213.50
Buildings	-	117.96	107.24	103.86	101.39	96.73
Machinery	-	237.32	206.45	193.64	191.2	178.46
Construction In Progress	-	402.77	12.41	9.57	2.12	3.78

Source: S&P Global Market Intelligence. Standard template. Financial Sources.